DOI QR코드

DOI QR Code

Analysis on Clinical Characteristics and Influencing Factors of Patients with Locoregionally Advanced Nasopharyngeal Carcinoma

  • Zheng, Wei (Department of Radiation Oncology, Fujian Provincial Cancer Hospital) ;
  • Xu, Yuan-Ji (The Shengli Clinical Medical College of Fujian Medical University) ;
  • Qiu, Su-Fang (Department of Radiation Oncology, Fujian Provincial Cancer Hospital) ;
  • Zong, Jing-Feng (Department of Radiation Oncology, Fujian Provincial Cancer Hospital) ;
  • Huang, Ling-Ling (The Shengli Clinical Medical College of Fujian Medical University) ;
  • Huang, Chao-Bin (Department of Radiation Oncology, Fujian Provincial Cancer Hospital) ;
  • Lin, Shao-Jun (Department of Radiation Oncology, Fujian Provincial Cancer Hospital) ;
  • Pan, Jian-Ji (Department of Radiation Oncology, Fujian Provincial Cancer Hospital)
  • Published : 2015.06.03

Abstract

Background: To explore the independent prognostic factors for the recurrence/metastasis of patients with locoregionally advanced nasopharyngeal carcinoma (LANPC). Materials and Methods: A total of 604 patients initially diagnosed as LANPC by pathohistology in Fujian Provincial Cancer Hospital were selected to analyze the relationship between the clinical pathological patterns, therapeutic protocols and clinical stages with the recurrence/metastasis of LANPC. Results: The 1-, 3- and 5-year locoregionally recurrent rates of LANPC patients were 2.0%, 9.5% and 12.9% respectively, with average recurrent period being 78 months. Univariate analysis results indicated that clinical stages had certain influence on the recurrent period of LANPC patients. However, COX regression models showed that ages, genders and clinical stages were not the independent prognostic factors influencing the recurrence. The 1-, 3- and 5-year metastatic rates of LANPC patients were 6.6%, 17.5% and 18.8% respectively, with average metastatic period of 73 months. Univariate analysis results demonstrated that ages, N stages, clinical stages, locations of lymph node, retropharyngeal lymph node and extracapsular invasion of lymph node had certain influence on the metastatic period of LANPC patients. Additionally, further COX regression analysis results suggested that T stages, reduction protocols and extracapsular invasion of lymph node were the independent prognostic factors influencing the metastasis of patients with LANPC, in which T stages and extracapsular invasion of lymph node were the pestilent factors while reduction protocols the protective factor. Conclusions: Induction chemotherapy is beneficial to LANPC patients with initial treatment, and the metastatic rate decreases greatly after the application of reduction chemotherapy.

Keywords

References

  1. Chen JL, Huang YS, Kuo SH, et al (2013). Intensity-modulated radiation therapy for T4 nasopharygeal carcinoma. Strahlenther Onkol, 189, 1001-8. https://doi.org/10.1007/s00066-013-0429-8
  2. Demirci S, Kamer S, Kara G, et al (2011). Does the prognosis of nasopharyngeal cancer differ among endemic and nonendemic regions? Acta Otolaryngol, 131, 852-60. https://doi.org/10.3109/00016489.2011.560188
  3. Dizman A, Coskun-Breuneval M, Altinisik-Inan G, et al (2014). Reirradiation with robotic stereotactic body radiotherapy for recurrent nasopharyngeal carcinoma. Asian Pac J Cancer Prev, 15, 3561-6. https://doi.org/10.7314/APJCP.2014.15.8.3561
  4. Hu S, Du J, Li D, et al (2014). Mitochondrial DNA haplogroup confers genetic susceptibility to nasopharyngeal carcinoma in chaoshanese from guangdong, china. PLOS ONE, 9, 87795. https://doi.org/10.1371/journal.pone.0087795
  5. Lee AW, Ng WT, Chan LLK, et al (2014).Evolution of treatment for nasopharyngeal cancer- Sucess and setback in the intensity-modulated radiotherapy era. Radiother Oncol, 110, 377-84. https://doi.org/10.1016/j.radonc.2014.02.003
  6. Li JX, Lu TX, Huang Y, et al (2012). Clinical characteristics of recurrent nasopharyngeal carcinoma in high-incidence area. Scientific World J, 2012, 719754.
  7. Li K, Lin GZ, Shen JC, et al (2014). Time trends of nasopharyngeal carcinoma in urban Guangzhou over a 12-year period (2000- 2011): declines in both incidence and mortality. Asian Pac J Cancer Prev, 15, 9899-903. https://doi.org/10.7314/APJCP.2014.15.22.9899
  8. Lin S, Pan J, Han L, Zhang X, et al (2009). Nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy: report on the 3-year outcome of a prospective series. Int J Radiat Oncol Biol Phys, 75, 1071-8. https://doi.org/10.1016/j.ijrobp.2008.12.015
  9. Lin SJ, Pan JJ, Han L, et al (2014). Update report of nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy and hypothesis of the optimal margin. Radiother Oncol, 110, 385-9. https://doi.org/10.1016/j.radonc.2014.01.011
  10. Qu S, Liang ZG, Zhu XD (2015). Advances and challenges in intensity-modulated radiotherapy for nasopharyngeal carcinoma. Asian Pac J Cancer Prev, 16, 1687-92. https://doi.org/10.7314/APJCP.2015.16.5.1687
  11. Wang Y, Zhao H, Zhang ZQ, et al (2014). MR imaging prediction of local control of nasopharyngeal carcinoma treated with radiation therapy and chemotherapy. Br J Radiol, 87, 20130657. https://doi.org/10.1259/bjr.20130657
  12. Wu F, Wang RS, Lu HM, et al (2014). Concurrent chemoradiotherapy in the locoregionally advanced nasopharyngeal carcinoma: Treatment outcomes of a prospective, multicentric clinical study. Radiother Oncol, 112, 106-11. https://doi.org/10.1016/j.radonc.2014.05.005
  13. Wu SY, Wu YH, Yang MW, et al (2014). Comparison of concurrent chemoradiotherapy versus neoadjuvant chemotherapy followed by radiation in patients with advanced nasopharyngeal carcinoma in endemic area: experience of 128 consecutive cases with 5 year follow-up. Plos One, 14, 787.
  14. Xu L, Pan J, Wu J, et al (2010). Factors associated with overall survival in 1706 patients with nasopharyngeal carcinoma: significance of intensive neoadjuvant chemotherapy and radiation break. Radiother Oncol, 96, 94-9. https://doi.org/10.1016/j.radonc.2010.04.006
  15. Zeng L, Tian YM, Sun XM, et al (2014). Intensity-modulated radiotherapy for stage IVA/IVB nasopharygeal carcinoma. Strahlenther Onkol, 190, 993-1000. https://doi.org/10.1007/s00066-014-0680-7

Cited by

  1. Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications vol.2016, pp.1875-8630, 2016, https://doi.org/10.1155/2016/9214056